Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...
manilatimes25m
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Under this transaction, Organovo will receive an upfront payment as well as milestones to be paid as FXR314 achieves key regulatory and commercial milestones. Lilly is acquiring all commercial and ...
stocknews33m
3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs
Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...
Eli Lilly and Company: Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...
Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The ...
Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Ottimo Pharma Strengthens Leadership Team with Senior Appointments
Ottimo Pharma ("Ottimo"), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment ...